Lannett Eyes Insulins Opportunity And Advances Respiratory Assets
CEO Tim Crew Sets Out Expectations For Pipeline As Firm Licenses Insulin Pen Patent
Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.
